| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
49,450,000 |
| Market
Cap: |
1.30(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$25.5 - $46.6 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 623 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Pacira BioSciences is a holding company. Through its subsidiaries, Co. is focused on non-opioid pain management. Co. has three commercialized non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesic approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, corticosteroid injection indicated for the management of OA knee pain; and ioveradeg®, a handheld device for delivering immediate, long-acting, drug-free pain control using controlled doses of cold temperature to a targeted nerve.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
119,323 |
119,323 |
201,796 |
291,198 |
| Total Sell Value |
$3,656,226 |
$3,656,226 |
$6,836,738 |
$12,122,941 |
| Total People Sold |
1 |
1 |
15 |
17 |
| Total Sell Transactions |
3 |
3 |
36 |
59 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Brege Laura |
Director |
– • – |
2023-06-05 |
4 |
AS |
$38.74 |
$23,244 |
D/D |
(600) |
9,547 |
|
-24% |
|
| Gaugler Daryl |
Chief Operating Officer |
• – – |
2023-06-05 |
4 |
AS |
$38.74 |
$38,740 |
D/D |
(1,000) |
23,591 |
|
-24% |
|
| Gaugler Daryl |
Chief Operating Officer |
• – – |
2023-05-31 |
4 |
AS |
$39.08 |
$97,700 |
D/D |
(2,500) |
24,591 |
|
-20% |
|
| Gaugler Daryl |
Chief Operating Officer |
• – – |
2023-05-31 |
4 |
OE |
$34.00 |
$85,000 |
D/D |
2,500 |
26,894 |
|
- |
|
| Hastings Paul J |
Director |
– • – |
2023-05-15 |
4 |
AS |
$41.85 |
$292,950 |
D/D |
(7,000) |
7,179 |
|
-22% |
|
| Hastings Paul J |
Director |
– • – |
2023-05-15 |
4 |
OE |
$29.90 |
$209,300 |
D/D |
7,000 |
14,179 |
|
- |
|
| Pace Gary W |
Director |
– • – |
2023-05-11 |
4 |
S |
$41.78 |
$209,527 |
D/D |
(5,015) |
139,675 |
|
18% |
|
| Pace Gary W |
Director |
– • – |
2023-05-11 |
4 |
OE |
$29.90 |
$209,300 |
D/D |
7,000 |
144,690 |
|
- |
|
| Brege Laura |
Director |
– • – |
2023-04-03 |
4 |
AS |
$40.72 |
$285,040 |
D/D |
(7,000) |
10,147 |
|
-9% |
|
| Brege Laura |
Director |
– • – |
2023-04-03 |
4 |
OE |
$29.90 |
$209,300 |
D/D |
7,000 |
17,147 |
|
- |
|
| Ellis Ronald J. Jr. |
Chief Strategy OfficerOfficer |
• – – |
2023-03-14 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
33,185 |
|
-6% |
|
| Reinhardt Max |
President, Rest of World |
• – – |
2022-10-07 |
4 |
AS |
$58.00 |
$80,040 |
D/D |
(1,380) |
31,378 |
|
-27% |
|
| Winston Roy |
Chief Medical Officer |
• – – |
2022-08-03 |
4 |
S |
$55.70 |
$26,513 |
D/D |
(476) |
44,992 |
|
28% |
|
| Slonin Jonathan |
Chief Clinical Officer |
• – – |
2022-08-03 |
4 |
S |
$55.70 |
$17,156 |
D/D |
(308) |
37,079 |
|
28% |
|
| Hastings Paul J |
Director |
– • – |
2022-07-11 |
4 |
AS |
$56.95 |
$30,354 |
D/D |
(533) |
7,179 |
|
-16% |
|
| Slonin Jonathan |
Chief Clinical Officer |
• – – |
2022-07-05 |
4 |
S |
$57.19 |
$52,842 |
D/D |
(924) |
37,387 |
|
9% |
|
| Laranjeira Charles Anthony |
Chief Technical Officer |
• – – |
2022-06-14 |
4 |
OE |
$38.35 |
$230,100 |
D/D |
6,000 |
41,752 |
|
- |
|
| Greenstreet Yvonne |
Director |
– • – |
2022-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,160 |
13,247 |
|
- |
|
| Pace Gary W |
Director |
– • – |
2022-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,160 |
137,690 |
|
- |
|
| Reinhardt Max |
President, Rest of World |
• – – |
2022-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
7,950 |
32,250 |
|
- |
|
| Kronenfeld Mark A. |
Director |
– • – |
2022-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,160 |
17,897 |
|
- |
|
| Hastings Paul J |
Director |
– • – |
2022-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,160 |
7,712 |
|
- |
|
| Laranjeira Charles Anthony |
Chief Technical Officer |
• – – |
2022-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
9,900 |
35,752 |
|
- |
|
| Laranjeira Charles Anthony |
Chief Technical Officer |
• – – |
2022-06-08 |
4 |
AS |
$59.08 |
$295,316 |
D/D |
(4,937) |
25,852 |
|
-9% |
|
| Reinhart Charles A. Iii |
Chief Financial Officer |
• – – |
2022-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
7,950 |
36,233 |
|
- |
|
781 Records found
|
|
Page 3 of 32 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.20 (0.77%) 
